Stratatech's genetically engineered skin tissue kills drug-resistant bacteria in mice
This article was originally published in Clinica
Executive Summary
Artificial skin grafts produced by regenerative medicine firm Stratatech have been shown to dramatically reduce bacterial infection, following genetic modification of the cells from which they are composed. The skin substitute product is efficacious against pathogen species that cannot be killed by antibiotics.